- Healthcare: Trials, Policy Headwinds and CEO Moves - Sep 10Regulatory holds, tougher Medicare Advantage thresholds and drug trial disappointments weighed on sentiment, while new imaging tech and clinical research offered longer-term upside. Read what matters for your portfolio heading into tomorrow.
- Healthcare Morning Brief - Sep 10Mixed clinical news, policy rulings and public-health developments set a cautious tone for healthcare on Sep 10. Read how a biotech miss, rural access rulings and a new cancer study could shape stocks and policy.
- Healthcare Momentum: Discoveries, FDA Stability - Sep 9Breakthrough preclinical work on an oral Ebola blocker, ARPA-H’s $62.7M push for AI heart-failure tools, and permanent FDA leadership drove the tape. You’ll find what moved the sector and what to watch next.
- Healthcare Morning Brief - Sep 9Biotech trial wins and AI advances headline a mixed healthcare tape today. You’ll want to track regulatory signals, workforce stress, and AI integration as catalysts that could move names like $ROIV and $BMY.
- Healthcare Wrap-Up Sep 8: Mixed SignalsToday’s Healthcare session mixed scientific breakthroughs and financing wins with clinical and regulatory setbacks. Read what moved providers, biotechs and policy ahead of tomorrow’s catalysts.
- Healthcare Mixed Signals: Trials, Costs and Policy Risks - Sep 8A Roivant mid-stage win lifts clinical momentum, but access, cost and regulatory stories temper the upside. Today's briefing breaks down trial news, payer strategy, policy risks, and AI data themes.
- Healthcare Advances, Trial Setbacks - Sep 7Cedars-Sinai rolled out three research advances in genetics, anxiety measurement and the small bowel microbiome, while Novo Nordisk halted two cardiovascular trials and the ADA faces ongoing internal review. Markets were closed for Labor Day, making these headlines the focal points heading into trading on Sep 8.
- Healthcare: Trial Setback & New Research - Sep 7A late-stage cardiovascular trial disappointment with $NVS and $IONS contrasts with encouraging preclinical findings for a repurposed cancer drug and new cardiac care guidance. Markets were closed for Labor Day; here’s what you should watch heading into Sep 8.
- Healthcare Hit by Novartis Setback - Sep 6 WrapA pivotal Novartis/Ionis cardiovascular drug failed to reduce heart events despite lowering Lp(a), raising questions about the class and trial design. New data on coronary artery calcium and care-use studies add mixed signals heading into the long weekend.
- Healthcare Headwinds After Novartis Setback - Sep 6Novartis' late-stage failure and Congress probing Oracle's VA EHR deal cast a shadow over the sector heading into the long weekend. AbbVie's myeloma win and steady dealmaking at Lilly provide counterpoints.
- Healthcare Mixed Signals - Sep 5 WrapA high-profile cardiovascular trial failure and hospital network disputes weighed on sentiment, while AbbVie’s myeloma win and new inflammation research offered upside. Markets were closed Sep 5; developments set the tone heading into Sep 8.
- Healthcare Sector Snapshot - Sep 5A busy weekend for healthcare news leaves investors with mixed signals: a major Novartis trial failure, fresh approvals and M&A momentum, plus policy and AI governance debates. Here’s what you need to know heading into the long weekend.
- Healthcare Wrap: Approvals, Deals, Disputes - Sep 4Drug approvals and deal activity drove positive headlines today, while hospital network fights, a widening E. coli recall, and EHR contract scrutiny tempered optimism. Read what you should watch next.
- Healthcare: Mixed Wins and Setbacks - Sep 4Today’s healthcare briefing covers breakthroughs, regulatory shifts and industry setbacks. You’ll find deal activity, R&D advances, safety concerns and what to watch next.
- Healthcare Evening Wrap - Sep 3Ultragenyx's Phase 3 setback dominated the tape, but GSK's $1.3B China deal and major AI biology funding kept deal flow upbeat. Read what moved the sector and what you should watch next.
- Healthcare Snapshot: FDA AI Pilot, Safety Woes - Sep 3Regulatory openings for generative AI devices clash with safety and compliance headwinds. Today's roundup covers the FDA TEMPO pilot, CAR-T study halts, Medicare audit findings, and company-level moves.
- Healthcare Wrap Sep 2: Research, Risks, RegulatorsToday's Healthcare wrap covers promising cancer research and new spatial genomics tools alongside safety setbacks, major data breaches, and a $15M settlement. Read what these mixed signals mean for your watchlist.
- Healthcare Snapshot: Novartis Win, Policy Shifts - Sep 2Novartis reported positive phase results for an MS pill while mid-cap biotechs and Medicaid face fresh pricing and coverage headwinds. Read what these mixed signals mean for your healthcare exposure today.
- Healthcare Wrap: Mixed Signals - Sep 1Today brought a big clinical win from Novartis, fresh basic-research breakthroughs and expanded drug-pricing pacts that widen revenue risk for makers. Read what moved healthcare and what to watch next.
- Healthcare: Genes, FDA Approval, Trial Halts - Sep 1Research breakthroughs in OCD genes and preeclampsia diagnostics join an FDA approval for a rare blood cancer drug, while CAR-T safety pauses and PBM litigation add caution. Read what you should watch today.
- Healthcare Wrap: Approvals, Deals, Pricing, Aug 31Today's healthcare tape served up an FDA approval and a major $2.9B acquisition, but fresh drug-pricing pacts and PBM litigation temper the outlook. Read what moved stocks, what matters to you, and what to watch next.
- Healthcare Innovation Momentum - Aug 31Today’s healthcare briefing spotlights renewed mRNA momentum, new immunology findings that could improve flu vaccines, and diagnostics advances that may boost clinical adoption. Read what you should watch and key catalysts for the sector.
- Healthcare: FDA Approval and New Guidelines - Aug 30A major FDA approval and new global cardiac and cardio-renal guidelines dominated healthcare headlines over the weekend. Read how these developments, plus drug trial fallout and emerging research, set the stage for Monday.
- Healthcare Mixed Signals Ahead of Labor Day - Aug 30Clinical studies at ESC and new corporate moves left the healthcare sector with mixed news heading into the long weekend. From cardio-oncology findings to RNA drug debate and a big $2.6B raise, here's what you need to know.
- Healthcare: Mixed Signals and New Data - Aug 29A mix of clinical progress, big financings and policy noise leaves healthcare sentiment balanced heading into the long weekend. Read how Novartis, Moderna and RNA drug debate could shape next week.
- Healthcare News Roundup - Aug 29Regulatory wins and big funding competed with a major trial setback in healthcare headlines as markets head into the long weekend. Read what you need to watch heading into next week.
- Healthcare: Aficamten, Moderna & Policy - Aug 28Clinical wins and fresh capital marked today’s healthcare headlines, but investor questions about RNA drugs and regulatory themes kept things mixed. Read what moved the sector and what to watch next.
- Healthcare Snapshot: Tezspire, Rasonque, Risks - Aug 28Blockbuster drug launches and new indications pushed product optimism, while a $542M Medicare settlement, policy uncertainty, and global health risks temper the outlook. Read what you should watch today.
- Healthcare: FDA Win and Blockbuster News - Aug 27Today's healthcare headlines were led by an FDA approval for Roivant's dermatomyositis therapy and blockbuster expectations after a new pancreatic cancer launch. Tezspire expansion data and skin biotech activity added to sector momentum.
- Healthcare: Pancreatic Drug Win, Policy Jitters - Aug 27Today’s healthcare headlines mix a blockbuster FDA clearance for pancreatic cancer with fresh questions about federal funding and Medicaid cuts. Read what you should watch in biotech, hospitals, and rural health.
- Healthcare Wrap Aug 26: Drug Win, Trial SetbackA fast FDA approval for a pancreatic cancer drug and a costly trial failure set a mixed tone across healthcare today. Digital-health deals and new predictive diagnostics add nuance as employers brace for higher costs.
- Healthcare Movers and Approvals - Aug 26FDA clearances and label expansions lead a wave of positive healthcare news today, from an Alzheimer’s blood test to a broader use for Jazz’s cancer drug. New vaccine and cardiovascular data add upside for diagnostics and therapeutics.
- Healthcare Faces Mixed Signals - Aug 25FDA clears a new Alzheimer's blood test while gene-therapy logistics improve for sickle cell patients. Rising costs, funding cuts, and public-health setbacks temper the optimism heading into tomorrow.
- Healthcare Clinical Hold, Funding Slump - Aug 25A second FDA clinical hold on Regenxbio and signs of slowing early-stage biotech funding set a cautious tone for healthcare on Aug 25. Policymaker moves on GLP-1 access and mixed research headlines add complexity for investors.
- Healthcare Sector Hits Regulatory Headwinds - Aug 24Clinical holds, contract losses and state cost controls set a cautious tone for healthcare stocks today. Scientific advances offer longer-term hope, but near-term risks are rising for biotech and providers.
- Healthcare Mix: Vaccine Win, Policy Risks - Aug 24Moderna and Merck report a breakthrough in a cancer vaccine while FDA signals forthcoming AI guidance. Public-health challenges and coverage-policy risk keep the picture mixed for healthcare investors.
- Healthcare Innovation Wrap - Aug 23Breakthroughs in microbiome metrics and glucose-sensing probiotics drove a positive innovation theme in healthcare on Aug 23. Read how these studies and vaccine coverage could shape near-term biotech focus.
- Healthcare Snapshot: Policy, Vaccines & Risks - Aug 23A mixed set of healthcare stories headlines the long weekend: a $750M Roche U.S. expansion, fresh HHS vaccine policy clues, GLP-1 affordability questions, and public-health alerts. Read what you should watch heading into Monday.
- Healthcare Sector Wrap - Aug 22Research breakthroughs, a $750M Genentech expansion and new vaccine policy clues dominated healthcare headlines heading into the long weekend. Here’s what you need to know for Monday.
- Healthcare Roundup: Tech, Policy & Drugs - Aug 22A mix of innovation, policy signals and mixed clinical data defines this Healthcare briefing. From the FDA clearing a robotic blood‑draw device to Roche's $750M expansion, read what you should watch heading into the long weekend.
- Healthcare Roundup - Aug 21Research wins and big pharma investments sat alongside policy friction and workforce strains today. Our evening wrap synthesizes the key moves, market signals, and what to watch next.
- Healthcare Sector Roundup - Aug 21Policy shifts and a new rare-disease drug approval set up a mixed trading day for healthcare. Read how DOJ guidance, state-level controversies, and Regeneron vs Ipsen will affect your watchlist.
- Healthcare Momentum on Approvals and Deals - Aug 20Approvals and a blockbuster Moderna reaction dominated healthcare news on Aug 20. Gene therapy and rare-disease wins, plus M&A and AI moves, set the stage for active trading tomorrow.
- Healthcare Risks and Innovation - Aug 20Today’s healthcare briefing highlights rising systemic pressures from staffing and insurance disruptions alongside select wins in research and AI adoption. Read what you need to watch for risk to margins, patient access, and regulatory scrutiny.
- Healthcare Mixed Signals on Policy and Biotech - Aug 19Policy moves and company-level scrutiny created volatility while new studies delivered useful clinical findings. Read what moved the Healthcare sector today and what you should monitor.
- Healthcare Snapshot: Trials, Deals and Risks - Aug 19AstraZeneca posts positive lung cancer data while BioMarin buys a rare-disease asset. Safety and policy stories, from a trial death to social media marketing, create mixed signals for investors.
- Healthcare Deals, Trial Results, Aug 18M&A and trial signals drove healthcare headlines today, from BioMarin and Leo Pharma buys to AstraZeneca lung cancer progress. Regulatory and workforce policy issues add caveats for investors.
- Healthcare Morning Brief - Aug 18Biotech clinical wins and exercise-mimicking research lead headlines while tribal health, food industry practices and a major insurer CFO change temper enthusiasm. Read what to watch today.
- Healthcare Faces Trial Setbacks, Lawsuits - Aug 17Clinical trial failures and corporate moves drove a cautious tone across healthcare today. You should watch upcoming readouts, legal developments, and pipeline milestones that could move stocks tomorrow.
- Healthcare Faces Policy and Resistance Risks - Aug 17Policy shocks and emerging biological threats set a cautious tone for healthcare markets today. From a new U.S. vaccine order to drug resistance in Uganda and an IRS probe into UnitedHealth, you should watch regulatory and operational risk closely.